Clinical Trial Update: Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies [Phase 3]

View source ↗

Summary

This trial update reports long-term safety and tolerability data for inclisiran in participants with familial hypercholesterolemia (heterozygous or homozygous) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia Heterozygous
• Familial Hypercholesterolemia Homozygous

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heterozygous or Homozygous Familial Hypercholesterolemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING